Upgrading the Chemotherapy Consent: Trading in Paper for Tablet.
JCO Oncol Pract
; 18(4): e632-e637, 2022 04.
Article
en En
| MEDLINE
| ID: mdl-34910564
ABSTRACT
PURPOSE:
Our institution participated in the Oncology Care Model, which required us to include many of the 13 elements of the National Academy of Medicine (NAM) care plan into care pathways for our patients. We optimized our existing chemotherapy consent process to meet this need and maximized completion.METHODS:
Our multidisciplinary committee developed a three-phase Plan-Do-Study-Act process in our breast cancer clinic (1) update and educate providers on our paper chemotherapy form with multiple components of the NAM care plan including prognosis and treatment effects on quality of life; (2) piloted an electronic chemotherapy consent form to decrease the administrative burden; and (3) autopopulated fields within the electronic consent. We assessed feedback after cycle 1 and created a Pareto chart. The outcome measure was percent completion of chemotherapy consent documents.RESULTS:
Baseline monthly random chart audit of 40 patients revealed 20% of paper chemotherapy consent forms were completed in their entirety among patients. When we re-educated clinicians about the new paper consent containing the NAM elements, compliance rose to nearly 30%. A Pareto chart confirmed that content redundancy and wordiness were leading to under-completion. After creating and piloting the electronic consent, compliance increased to 90%. Finally, autopopulation with drop-down selections increased and sustained completion to 100%.CONCLUSION:
Incorporating regulatory requirements into an existing workflow using Plan-Do-Study-Act methodology can reduce administrative burden on clinicians. Additional use of innovative technology can further increase clinician compliance with regulatory requirements while delivering high-value quality care to patients with cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Neoplasias
Tipo de estudio:
Guideline
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
JCO Oncol Pract
Año:
2022
Tipo del documento:
Article